Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PSA-3 vaccine
- Development stage
- Unknown
- Lead developer
- National Cancer Institute
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Administration
- Subcutaneous
01
Overview
PSA-3 is a peptide-based cancer vaccine candidate developed by the University of Maryland for the treatment of prostate cancer. It consists of a specific 10-amino acid epitope (VISNDVCAQV) derived from the prostate-specific antigen (PSA) protein, specifically residues 154-163. The vaccine is designed to be HLA-A2 restricted, aiming to stimulate a cytotoxic T-lymphocyte (CTL) response against tumor cells that express PSA. In clinical trials, PSA-3 is typically administered in combination with the adjuvant Montanide ISA-51 (NSC 675756) to enhance its immunogenicity. Development has primarily focused on patients with biochemical recurrence of prostate cancer following radical prostatectomy.
- Other names
- Prostate Specific Antigen-3 vaccinePSA-3 peptide vaccinePSA3 peptide vaccinePSA 3 peptide vaccinePSA-3 peptidePSA3 peptidePSA 3 peptide
02
Targets
PSA (Puromycin-sensitive aminopeptidase)PSA:154-163/HLA-A2 (Prostate-specific antigen (154–163) peptide-HLA-A*02:01 complex)PSA-TCR (T-cell receptor specific for Prostate-specific antigen (PSA) peptide 154–163 presented by Human leukocyte antigen A*02:01 (HLA-A*02:01))HLA-A*02:01 (Human leukocyte antigen A*02:01)
Beyond the preview
Go deeper on PSA-3 vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PSA-3 vaccine.